A role of donor-specific HLA antibodies (DSA) in graft failure after SCT has been suggested, but the relevance of DSA in unmanipulated haploidentical SCT (haplo-SCT) remains unknown. We prospectively examined HLA antibodies using the Luminex-based single Ag assay for 79 adult patients undergoing unmanipulated haplo-SCT. Among them, 16 (20.2%) were HLA Ab-positive, including five patients with antibodies not corresponding to donor HLA Ags and 11 DSA-positive patients. Of the 11 DSA-positive patients, five received treatments to decrease DSA levels, including two, who received plasma exchange and rituximab, two who received platelet transfusions from healthy-related donors having DSAcorresponding HLA Ags and one who received bortezomib. Platelet transfusion was the most simple and effective treatment option for class I DSA. The cumulative incidence of neutrophil recovery was significantly lower in pretransplant (post-treatment) DSA-positive patients than in DSA-negative patients (61.9 vs 94.4%, P ¼ 0.026). Notably, three of five patients with high levels of DSA had graft failure. Donors should be selected on the basis of an evaluation of HLA antibodies. If haplo-SCT from donors with HLA Ags that correspond to high levels of DSA must be performed, then recipients should be treated for DSA to improve the chances of successful donor engraftment.
Introduction
Graft failure is a life-threatening complication following allo-SCT. An early study in the 1980s by Anasetti et al. 1 clearly demonstrated that the incidence of graft failure increases in relation to the disparity of HLA Ags: 2% in HLA genotypically identical, 7% in HLA phenotypicallymatched haploidentical, 9% in HLA-1 locus-mismatched haploidentical and 21% in HLA-2 loci-mismatched haploidentical BMT. This study indicated the involvement of HLA antibodies in the mechanism of graft failure by demonstrating that patients with a positive crossmatch for anti-donor T cells or B cells had a significantly higher rate of graft failure (39%) than patients with a negative crossmatch (10%). The association between a positive crossmatch and graft failure has been confirmed by other investigators. 2 On the other hand, host immunocompetent cells, either T cells or natural-killer cells, have been generally considered to have a major role in the mechanism of immune rejection. In fact, previous studies demonstrated that host T cells that recognize donor HLA Ags emerge at the time of graft failure. 3, 4 Nevertheless, recent animal studies have demonstrated that preformed Ab, not primed T cells, is the initial and major barrier to BM engraftment in allosensitized recipients. 5 Moreover, Ab-mediated rejection is a well-recognized cause of treatment failure in the field of solid organ transplantation. [6] [7] [8] [9] Furthermore, novel solidphase immunoassays, including Luminex single-Ag assays that use purified preparations of molecules corresponding to a single HLA Ag, allow accurate identification and quantification of specific HLA antibodies. 10 Recent studies indicate that the risk for both Ab-mediated rejection and graft loss after kidney transplantation directly correlate with peak levels of donor-specific HLA antibodies (DSA), as measured by Luminex single-Ag assays. 11 In this study, we examined HLA antibodies as part of the pretransplant work-up for patients undergoing haploidentical SCT (haplo-SCT). The management of patients with DSA was left to their physicians, as the impact of DSA on graft failure after unmanipulated haplo-SCT remains unclear. Here, we present the results of a retrospective analysis of prospectively collected data.
Patients and methods

Patients
We prospectively examined HLA antibodies as a work-up for 79 adult patients undergoing haplo-SCT between January 2008 and March 2010. In the present study, haplo-SCT was defined as SCT from donors who share one of the two HLA haplotypes, regardless of the number of HLA-mismatched loci in A, B and DR locus in graftversus-host (GVH) or host-versus-graft (HVG) vectors; this definition was used because antibodies against HLA Ags, such as HLA-DP, which are not routinely tested in the settings of related donor transplantation, may also cause Ab-mediated rejection. 12, 13 This study was approved by the Institutional Review Board of the Hyogo College of Medicine. All patients provided informed consent before participating in the study.
Measurement of HLA Ab levels
Patient plasma/serum was screened for class I (i.e., HLA-A/B/C) and class II (i.e., HLA-DR/DP/DQ) HLA antibodies with a LABScreen PRA Kit (One Lambda, Canoga Park, CA, USA). Positive samples were further tested for the specificity of the Ab, using a LABScreen Single Antigen Kit (One Lambda). Fluorescence was measured with a Luminex100 flow analyzer (Luminex, Austin, TX, USA) and the data were analyzed with the LABScan 100 software (One Lambda). Median fluorescence intensity (MFI) of the PRA beads' reactions was obtained from the output file generated by the flow analyzer, adjusted for the background signal using the formula: sample beadsÀnegative control beads. The fluorescence intensity of negative control beads was less than 100 and the intensity of positive control beads was greater than 9000. If the sample data did not fit these conditions, the serum or plasma was treated with ADSORB OUT beads (One Lambda) to reduce background fluorescence. For confirmation and identification of sample specificity, all samples with fluorescence intensity greater than 500 were tested with single Ag beads. MFI was adjusted for the background signal using the formula described above. HLA allele typing of patients and donors was performed for at least A, B and DRB1 loci routinely. When HLA antibodies targeting HLA-C, DP or DQ loci were detected in patients, HLA allele typing of their donors for those loci was additionally performed.
Transplantation protocols
Institutional protocols for haplo-SCT from two to three Ag-mismatched (in GVH vector) donors, either with myeloablative or reduced-intensity conditioning, have been previously described. 14, 15 Briefly, the protocol of myeloablative haplo-SCT from HLA 2-3 Ag-mismatched donors includes a preparative regimen consisting of CY (60 mg/kg Â 2), TBI (8-10 Gy) and fludarabine (30 mg/m 2 Â 4), with or without Ara-C (2 g/m 2 Â 4), GVHD prophylaxis including a combination of tacrolimus, MTX, mycophenolate mofetil and methylprednisolone (2 mg/kg). For HLA 0-1 Ag-mismatched patients, conventional TBI (12 Gy) was used for preparative conditioning, with less intensive GVHD prophylaxis (CYA and MTX for 0 Ag-mismatched patients; tacrolimus and methylprednisolone for one Ag-mismatched patient). The protocol of reduced-intensity haplo-SCT from HLA 2-3 Ag-mismatched donors included a preparative regimen consisting of fludarabine (30 mg/m 2 Â 6), BU (4 mg/kg Â 2) or melphalan (70 mg/m 2 Â 2) and anti-T-lymphocyte globulin/anti-thymocyte globulin, with or without Ara-C (2 g/m 2 Â 4), GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg per day). Some patients received low dose TBI (2-4 Gy) in addition to the preparative regimen described above. For HLA 0-1 Agmismatched patient, less intensive GVHD prophylaxis (CYA, with or without MTX for 0 Ag-mismatched patients, tacrolimus and methylprednisolone for one Agmismatched patient) was used. Age criteria for reducedintensity conditioning regimen were 40 years or older for HLA 2-3 Ag-mismatched SCT and 50 years or older for HLA 0-1 Ag-mismatched SCT. Patients with comorbidities or those who had undergone earlier SCT also received reduced-intensity conditioning regimen. In general, BM was the stem cell source in myeloablative haplo-SCT and PBSCs were the stem cell source in reduced-intensity haplo-SCT. I.v. Ig (100 mg/kg per week) was administered to all patients for 2 months after transplantation, regardless of the presence of HLA antibodies.
Chimerism analysis
Donor chimerism was determined serially in the T cell and neutrophil-enriched cell fractions of peripheral blood and BM. The methodology used for cell separation and chimerism analysis has been detailed elsewhere. 14, 16 Briefly, T cells were enriched by a negative selection system (RosetteSep; StemCell, Vancouver, Canada) to a purity of 495% and granulocytes were recovered from the Ficoll-RBC interface with a purity of 499%. Chimerism analysis involved quantitative PCR of informative STRs in the recipient and donor. DNA was amplified with fluorescent PCR primers for markers that would distinguish the donor and recipient alleles. Fluorescent PCR products were separated with an Applied Biosystems 310 Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA), and the GeneScan software (Applied Biosystems) was used to correlate allele peak areas with the percentage of donor or recipient DNA.
Definitions
Patients were defined as Ab-negative when the screening test with LABScreen PRA was negative, or the MFI in the LABScreen Single Antigen analysis was less than 5000. Patients were defined as non-DSA-positive when they had HLA-antibodies with MFI 45000, not corresponding to the mismatched donor HLA Ag. Patients were defined as DSA-positive when they had HLA-antibodies with MFI 45000, corresponding to the mismatched donor HLA Ag. DSA with MFI 410 000 was defined as high levels of DSA.
Pretransplant DSA levels were defined as DSA levels of samples that were taken most immediately before transplantation (day À1 or 0 in the majority of the patients). In the analysis of neutrophil engraftment, only patients with pretransplant (post-treatment) DSA (MFI 45000) were treated as DSA-positive, whereas the others, including patients who had been DSA-positive at the time of screening and had subsequently turned Ab-negative, with or without treatments for DSA, were treated as DSA-negative.
Neutrophil recovery was defined as an ANC of at least 500 Â 10 6 /L for three consecutive tests. Platelet recovery was defined as a platelet count of at least 20 Â 10 9 /L without transfusion support. Graft failure was defined as either (1) no appearance or complete loss of donor-derived neutrophils using STR chimerism analysis by day 18 or (2) an absence of neutrophil recovery by day 60. Platelet engraftment was defined as platelet recovery in the absence of graft failure.
Statistical analysis
Proportions were compared between groups using Fisher's exact test. Cumulative incidence was used to estimate the rates of neutrophil engraftment and platelet engraftment by treating non-event deaths as a competing risk. The Gray test was used for group comparisons of cumulative incidence. Multivariate analysis was performed with logistic regression analysis to identify risk factors for achieving or not achieving donor neutrophil engraftment, irrespective of time to neutrophil recovery. Clinical factors that were associated with at least borderline significance (Po0.10) in the univariate analyses were subject to multivariate analysis using backward stepwise modeling. Finally, P-values less than 0.05 were considered statistically significant. The following factors were considered: patient age (o50 vs 450 years), sex, disease status (remission vs no remission), intensity of preparatory regimen (myeloablative vs reduced-intensity), stem cell source (BM vs PBSC), pretransplant presence of DSA and numbers of HLA mismatches in the GVH vector (0-1 vs 2-3) and HVG vector (0-1 vs 2-3).
Results
Patient characteristics
The characteristics of the patients are summarized in Table 1 . Among 79 screened patients, 16 (20.2%) were HLA Ab-positive, including five non-DSA-positive and 11 DSA-positive patients. The proportion of females among DSA-positive patients was significantly higher than among Ab-negative patients (40 vs 91%, P ¼ 0.0022). The majority of DSA-positive patients received grafts from their offspring ('offspring to mother transplantation'). There were no significant differences in the median age of recipients or disease status at the time of transplantation between the groups. The majority of patients received grafts that were HLA 2-3 Ag mismatched in both GVH and HVG vectors. The characteristics of DSA-positive patients are summarized in Table 2 . Ten of 11 DSA-positive patients were parous women.
Outcomes of treatment for HLA antibodies Among 11 DSA-positive patients, five received treatments in an attempt to decrease DSA levels (Table 3) . Treatments for HLA antibodies were determined by their physician according to the factors including performance status of the patients, urgency of SCT and the class of HLA antibodies (class I, class II or both). Two patients (nos. 2 and 4) received plasma exchange and a single dose of rituximab (375 mg/m 2 ); two patients (nos. 6 and 8) received platelet transfusion from healthy-related donors having DSAcorresponding HLA Ags in an attempt to absorb DSA, and one patient (no. 7) received bortezomib. Plasma exchange using 40 units of fresh frozen plasma was performed on day À11 in patient no. 2 and on days À17, À15 and À13 in patient no. 4 (Figures 1a and b) . These earlier timings were intended to complete the plasma exchange procedures before the beginning of the conditioning regimen to avoid the influence of plasma exchange on the pharmacokinetics of the chemotherapeutic agents used in the conditioning regimen. Reduction in DSA levels after plasma exchange was temporary and DSA levels rebounded to baseline levels within 1 week of the last procedure in patient no. 4 ( Figure 1b ). Transfusion of a large volume of platelets (40 units) expressing DSAcorresponding HLA Ags on day À1 resulted in rapid and remarkable reduction of DSA levels in both patients receiving this treatment (Figures 1c and d) . Bortezomib was administered to a single patient at the dose of 1.3 mg/m 2 on days À18 and À15, combined with dexamethasone (20 mg) on days À18, À17, À15 and À14; the patient showed only moderate reduction in DSA levels, from 10 199 on day À25 to 9289 on day 0. A single patient (no. 9) showed a reduction of DSA without any particular treatment for DSA.
Engraftment
As a result of the treatments for DSA described above, four patients became DSA negative and thus, 67, 5 and 7 patients were Ab-negative, non-DSA-positive and DSApositive, respectively, at the time of transplantation. The cumulative incidence of donor neutrophil engraftment was significantly lower in DSA-positive patients than in DSAnegative patients (61.9 vs 94.4%, P ¼ 0.026; Figure 2 ). The cumulative incidence of platelet engraftment at 6 months after transplantation was also significantly lower in DSA-positive patients than in DSA-negative patients (28.6 vs 79.6%, P ¼ 0.035). Notably, three of five patients with high levels of pretransplant DSA (MFI 410 000) developed graft failure and none of the other two DSApositive patients with lower DSA levels (MFI 5000-10 000) had graft failure. Interestingly, none of five patients who were treated to decrease DSA levels experienced engraftment failure, even two of them (no. 4 and 7) remained DSA positive at the time of transplantation. Multivariate analysis showed that pretransplant presence of DSA (MFI 45000) was the only significant risk factor for graft failure (P ¼ 0.006). Among 72 DSA-negative patients, three of the Abnegative patients and none of the non-DSA-positive patients developed graft failure. One of the three Abnegative patients, who had graft failure was HLA homozygous, thus had HLA mismatches only in the HVG vector (HLA matched in the GVH vector and three Ag mismatched in the HVG vector). All of these three patients were reviewed for Ab levels with single Ag analysis, but none had HLA antibodies with MFI 41000.
HLA Ab levels after SCT DSA levels rapidly decreased in all patients who achieved donor engraftment (Table 3) . Notably, DSA levels in three of four patients (no. 1, 3 and 7), who achieved donor engraftment in spite of the presence of pretransplant DSA, demonstrated a 50% reduction within 3 days and 75% reduction within a week after transplantation. In one patient (no. 4) who showed a slower reduction of DSA levels, neutrophil recovery was delayed until day 24. Moreover, the patient was dependent on intermittent administration of G-CSF, RBC and platelet transfusion for almost a year. Furthermore, DSA levels in three patients who developed graft failure (no. 5, 10 and 11) remained high after SCT. Of note, DSA levels never decreased below 50% of pretransplant levels in one patient (no. 10) who had autologous hematopoietic recovery. 
Discussion
The present study had four significant findings. First, we demonstrated that the presence of pretransplant DSA is associated with a higher rate of graft failure following unmanipulated haplo-SCT. Notably, among five patients with high levels of pretransplant DSA (MFI 410 000), three patients developed primary graft failure. Recently, three independent groups reported that DSA is a risk factor for graft failure after SCT involving different stem cell sources. 13, 17, 18 . In a case-control study, Spellman et al. 13 demonstrated that the presence of DSA in recipients of unrelated SCT was associated with a higher rate of graft failure, defining DSA-positive as MFI 42000 for Luminextested samples, or a mean fluorescence channel shift of more than 40 for single Ag flow bead assays. Moreover, in a retrospective analysis of 386 patients, Takanashi et al. 18 demonstrated the impact of HLA antibodies on engraftment after myeloablative single-unit cord blood transplantation, defining Ab-positive as MFI X1000 or MFI 4800, when there was a cross-reactive HLA Ag. Notably, the cumulative incidence of neutrophil recovery in DSApositive patients (32%) was significantly lower than that in Ab-negative patients (83%) and in non-DSA-positive patients (73%). Furthermore, Ciurea et al. 17 demonstrated that the presence of pretransplant DSA is associated with a high rate of graft failure, in cases of haplo-SCT with CD34-positive cell selection as a means of T-cell depletion from the graft. Three of four (75%) pretransplant DSA-positive patients (MFI 41500) failed to engraft, compared with 1 of 20 (5%) DSA-negative patients (P ¼ 0.008).
Compared with these previous studies, the impact of DSA in unmanipulated haplo-SCT appears to be smaller than that of cord blood transplantation and T cell-depleted haplo-SCT; in the present study, graft failure was not observed in patients with DSA with MFI 5000-10 000. The difference between the present study and other studies can be attributed to several factors, including a larger number of infused progenitor cells and T cells in unmanipulated haplo-SCT. The total number of infused cells that express the HLA Ag is thought to be particularly important, because these cells potentially absorb DSA and thus ameliorate the effects of DSA on stem cells. In fact, we demonstrated that DSA levels in the majority of the engrafted patients decreased rapidly after transplantation.
Second, we obtained valuable information about the usefulness of various treatment procedures for DSA even though the number of patients was not sufficient to draw solid conclusions. Notably, platelet transfusion from donors with DSA-corresponding HLA Ags on day À1 was particularly effective in reducing DSA levels on day 0, which is consistent with a previous case report. 19 Platelet transfusion has the advantage of being a simple procedure. However, a disadvantage is the inherent lack of effectiveness for class II antibodies, as class II Ags are not expressed on platelets. Although several previous reports demonstrated the efficacy of plasma exchange, 12, 17 its effect in the present study was unsatisfactory because of the early rebound of DSA levels. This inconsistency is most likely due to variations in the timing of the procedure. Like platelet transfusion, plasma exchange is aimed at eliminating existing antibodies rather than preventing the production of new antibodies. Our results suggest that plasma exchange should be performed immediately before transplantation. However, unlike platelet transfusion, plasma exchange is challenging to perform during or after preconditioning treatments because of the risks that are associated with the procedure.
The effects of rituximab and bortezomib on the reduction of DSA levels could not be determined in the present study because of the short duration of observations. Nevertheless, a recent randomized prospective trial of rituximab for acute rejection in pediatric renal transplantation demonstrated that it has some benefits for the recovery of graft function and improvement of biopsy rejection scores without reduction in DSA levels. 20 In addition, bortezomib has received recent attention in studies showing that it directly eliminates Ab-producing plasma cells and thus prevents Ab-mediated graft rejection after renal transplantation. [21] [22] [23] Moreover, improvement of platelet transfusion refractoriness was observed in a patient with HLA class I antibodies with the treatment of bortezomib for multiple myeloma. 24 The effectiveness of high-dose i.v. Ig, which was demonstrated in cases of solid organ transplantation and murine study of BMT, 5,25 also could not be determined in the present study, as all of the patients regularly received moderate doses of Ig. Collectively, platelet transfusion from donors having DSA-corresponding HLA Ags on day À1 appears to be the simplest and most effective treatment option for class I DSA. The role of bortezomib in preventing Ab-mediated graft failure following SCT needs to be investigated in future studies, using a prospective approach. Plasma exchange should be reserved for class II DSA cases. Meanwhile, regardless of the modality used, none of the treated patients, including two with relatively high DSA levels even after treatment, experienced graft failure. Thus, it could be also possible to speculate that treatment for DSA have some beneficial effect, which could not be fully reflected by the decrement of Ab levels.
Third, we demonstrated that the kinetics of DSA levels after SCT were remarkably different between patients who did or did not achieve engraftment. Moreover, one patient who showed a slower reduction in DSA levels, in spite of achieving donor engraftment, had an exceptionally delayed hematopoietic recovery. It is tempting to speculate that the kinetics of DSA levels reflects the status of both ablation of host Ab-producing cells and donor hematopoietic engraftment. Initial reduction in DSA levels is probably due to the absorption of antibodies by the graft itself. Continuously high DSA levels most likely reflect the production of DSA by host residual Ab-producing cells and the absence of donor cells which would absorb antibodies. Collectively, these findings suggested the possibility of early prediction of Ab-mediated graft failure by serial monitoring of DSA levels after SCT.
Finally, our findings identified a possible problem that could be associated with offspring-to-mother transplantation. Notably, 8 of 11 DSA-positive patients were from offspring donors. Although pregnancy may result in fetomaternal tolerance, which is the basis for haplo-SCT from non-inherited maternal Ag-mismatched related donors, 26, 27 it also may result in allosensitization. 28 In fact, several case reports demonstrated the occurrence of accelerated rejection following offspring-to-mother renal transplantation, even in cases in which cross-match tests were negative. 29, 30 The present study has several limitations. First, as the Luminex-based single Ag assay is very sensitive, variations in results could occur within or between laboratories. As we defined Ab positive as MFI 45000, which is considerably higher than in other studies, the influence of inherent measurement errors should be negligible. Nevertheless, recent studies demonstrated that DSA levels identified with Luminex assays are not always cytotoxic. Strong cytotoxic activity of DSA is associated with a higher rate of renal graft loss, but is not correlated with Ab level. 31 Further studies are needed to identify clinically relevant DSA in graft failure after SCT. Second, the present study examined only HLA IgG antibodies as did aforementioned studies. 13, 17, 18 IgM and non-HLA alloantibodies, such as antibodies against MHC class I-related chain A molecules, are possibly involved in the mechanism of graft failure in HLA Ab-negative patients.
In conclusion, we demonstrated that the presence of pretransplant DSA is associated with a high rate of graft failure after unmanipulated haplo-SCT, although the impact appears to be smaller than in cord blood transplantation and T cell-depleted haplo-SCT. HLA antibodies should be examined as a part of the pretransplant work-up, especially in parous female patients. Furthermore, donors who have HLA Ags that correspond to high levels of DSA should be avoided; however, if haplo-SCT from such donors must be performed, recipients should be treated for DSA to improve the chances of successful donor engraftment.
